149 related articles for article (PubMed ID: 9052725)
1. CD8+,CD38+ lymphocyte percent: a useful immunological marker for monitoring HIV-1-infected patients.
Mocroft A; Bofill M; Lipman M; Medina E; Borthwick N; Timms A; Batista L; Winter M; Sabin CA; Johnson M; Lee CA; Phillips A; Janossy G
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Feb; 14(2):158-62. PubMed ID: 9052725
[TBL] [Abstract][Full Text] [Related]
2. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression.
Liu Z; Cumberland WG; Hultin LE; Prince HE; Detels R; Giorgi JV
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Oct; 16(2):83-92. PubMed ID: 9358102
[TBL] [Abstract][Full Text] [Related]
3. Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients.
Bofill M; Mocroft A; Lipman M; Medina E; Borthwick NJ; Sabin CA; Timms A; Winter M; Baptista L; Johnson MA; Lee CA; Phillips AN; Janossy G
AIDS; 1996 Jul; 10(8):827-34. PubMed ID: 8828739
[TBL] [Abstract][Full Text] [Related]
4. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study.
Giorgi JV; Liu Z; Hultin LE; Cumberland WG; Hennessey K; Detels R
J Acquir Immune Defic Syndr (1988); 1993 Aug; 6(8):904-12. PubMed ID: 7686224
[TBL] [Abstract][Full Text] [Related]
5. During HIV infection, CD4+ CD38+ T-cells are the predominant circulating CD4+ subset whose HLA-DR positivity increases with disease progression and whose V beta repertoire is similar to that of CD4+ CD38- T-cells.
Ramzaoui S; Jouen-Beades F; Gilbert D; Borsa-Lebas F; Michel Y; Humbert G; Tron F
Clin Immunol Immunopathol; 1995 Oct; 77(1):33-41. PubMed ID: 7554481
[TBL] [Abstract][Full Text] [Related]
6. Indicators of T-cell activation: correlation between quantitative CD38 expression and soluble CD8 levels in asymptomatic HIV+ individuals and healthy controls.
Lenkei R; Bratt G; Holmberg V; Muirhead K; Sandström E
Cytometry; 1998 Oct; 33(2):115-22. PubMed ID: 9773871
[TBL] [Abstract][Full Text] [Related]
7. Quantitative alterations of the functionally distinct subsets of CD4 and CD8 T lymphocytes in asymptomatic HIV infection: changes in the expression of CD45RO, CD45RA, CD11b, CD38, HLA-DR, and CD25 antigens.
Benito JM; Zabay JM; Gil J; Bermejo M; Escudero A; Sánchez E; Fernández-Cruz E
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Feb; 14(2):128-35. PubMed ID: 9052721
[TBL] [Abstract][Full Text] [Related]
8. Expression of CD28 and CD38 by CD8+ T lymphocytes in HIV-1 infection correlates with markers of disease severity and changes towards normalization under treatment. The Swiss HIV Cohort Study.
Bürgisser P; Hammann C; Kaufmann D; Battegay M; Rutschmann OT
Clin Exp Immunol; 1999 Mar; 115(3):458-63. PubMed ID: 10193418
[TBL] [Abstract][Full Text] [Related]
9. A single measurement of CD38CD8 cells in HIV+, long-term surviving injecting drug users distinguishes those who will progress to AIDS from those who will remain stable.
Froebel KS; Raab GM; D'Alessandro C; Armitage MP; MacKenzie KM; Struthers M; Whitelaw JM; Yang S
Clin Exp Immunol; 2000 Oct; 122(1):72-8. PubMed ID: 11012621
[TBL] [Abstract][Full Text] [Related]
10. Cell cycling in HIV infection: analysis of in vivo activated lymphocytes.
Mahalingam M; Pozniak A; McManus TJ; Vergani D; Peakman M
Clin Exp Immunol; 1995 Dec; 102(3):481-6. PubMed ID: 8536361
[TBL] [Abstract][Full Text] [Related]
11. Elevated relative fluorescence intensity of CD38 antigen expression on CD8+ T cells is a marker of poor prognosis in HIV infection: results of 6 years of follow-up.
Liu Z; Hultin LE; Cumberland WG; Hultin P; Schmid I; Matud JL; Detels R; Giorgi JV
Cytometry; 1996 Mar; 26(1):1-7. PubMed ID: 8809474
[TBL] [Abstract][Full Text] [Related]
12. Activation of CD8 T cells normalizes and correlates with the level of infectious provirus in tonsils during highly active antiretroviral therapy in early HIV-1 infection.
Dyrhol-Riise AM; Voltersvik P; Olofsson J; Asjö B
AIDS; 1999 Dec; 13(17):2365-76. PubMed ID: 10597778
[TBL] [Abstract][Full Text] [Related]
13. CD8+CD38+ and CD8+DR+ peripheral blood lymphoid subsets of HIV-infected intravenous drug abusers correlate with CD4+ cell counts and proliferation to mitogens.
Echaniz P; Arrizabalaga J; Iribarren JA; Cuadrado E
Cell Immunol; 1993 Aug; 150(1):72-80. PubMed ID: 7688270
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance in HIV infection of immune activation represented by cell surface antigen and plasma activation marker changes.
Plaeger S; Bass HZ; Nishanian P; Thomas J; Aziz N; Detels R; King J; Cumberland W; Kemeny M; Fahey JL
Clin Immunol; 1999 Feb; 90(2):238-46. PubMed ID: 10080836
[TBL] [Abstract][Full Text] [Related]
15. CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+ CD38- CD8+ cells is associated with subsequent stable CD4+ cell levels. The Multicenter AIDS Cohort Study Group.
Giorgi JV; Ho HN; Hirji K; Chou CC; Hultin LE; O'Rourke S; Park L; Margolick JB; Ferbas J; Phair JP
J Infect Dis; 1994 Oct; 170(4):775-81. PubMed ID: 7930717
[TBL] [Abstract][Full Text] [Related]
16. Different meaning of CD38 molecule expression on CD4+ and CD8+ cells of children perinatally infected with human immunodeficiency virus type 1 infection surviving longer than five years.
de Martino M; Rossi ME; Azzari C; Gelli MG; Galli L; Vierucci A
Pediatr Res; 1998 Jun; 43(6):752-8. PubMed ID: 9621984
[TBL] [Abstract][Full Text] [Related]
17. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection.
Plana M; García F; Gallart T; Tortajada C; Soriano A; Palou E; Maleno MJ; Barceló JJ; Vidal C; Cruceta A; Miró JM; Gatell JM
AIDS; 2000 Sep; 14(13):1921-33. PubMed ID: 10997396
[TBL] [Abstract][Full Text] [Related]
18. CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency.
Liu Z; Cumberland WG; Hultin LE; Kaplan AH; Detels R; Giorgi JV
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Aug; 18(4):332-40. PubMed ID: 9704938
[TBL] [Abstract][Full Text] [Related]
19. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir.
Kelleher AD; Carr A; Zaunders J; Cooper DA
J Infect Dis; 1996 Feb; 173(2):321-9. PubMed ID: 8568292
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection.
Giorgi JV; Lyles RH; Matud JL; Yamashita TE; Mellors JW; Hultin LE; Jamieson BD; Margolick JB; Rinaldo CR; Phair JP; Detels R;
J Acquir Immune Defic Syndr; 2002 Apr; 29(4):346-55. PubMed ID: 11917238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
